Brief: Ascelia Pharma Q4 Operating Loss Widens To SEK 14.5 Million

Ascelia Pharma AB

22/08/2019 07:14

Aug 22 (Reuters) - Ascelia Pharma AB  ACELP.ST :
    * Q4 OPERATING RESULT OF SEK -14.5M (SEK -8.2M)
    * NOW HAVE A FULLY FINANCED PHASE III STUDY OF MANGORAL,
WHICH WE
PLAN TO INITIATE LATER IN 2019 WITH FINAL RESULTS LATE 2020 OR
AT BEGINNING OF 2021

Source text for Eikon:  ID:nWkr8YQDbJ 
Further company coverage:  ACELP.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))